Monopar Therapeutics

OverviewSuggest Edit

Monopar Therapeutics is a biopharmaceutical company focused on developing innovative drugs and drug combinations to improve clinical outcomes for cancer patients. The company currently has three compounds in development: Validive, a Phase 3-ready molecule for the prevention and treatment of severe oral mucositis in patients undergoing radiotherapy for oropharyngeal cancer, Camsirubicin, a novel doxorubicin analog engineered to eliminate the cardiotoxic side effects typically generated by anthracycline-based cancer drugs, and MNPR-101, a novel first-in-class humanized monoclonal antibody to the urokinase plasminogen activator receptor for the treatment of advanced cancers.

TypePublic
Founded2014
HQWilmette, US
Websitemonopartx.com

Latest Updates

Employees (est.) (Aug 2019)4
Share Price (Feb 2020)$10 (-8%)

Key People/Management at Monopar Therapeutics

Chandler D. Robinson

Chandler D. Robinson

Co-Founder and Chief Executive Officer
Christopher M. Starr

Christopher M. Starr

Co-Founder and Executive Chairman
Kim R. Tsuchimoto

Kim R. Tsuchimoto

Chief Financial Officer
Andrew P. Mazar

Andrew P. Mazar

Co-Founder and Executive Vice President, Research and Development Chief Scientific Officer
Patrice Rioux

Patrice Rioux

Acting Chief Medical Officer
Show more

Monopar Therapeutics Office Locations

Monopar Therapeutics has an office in Wilmette
Wilmette, US (HQ)
1000 Skokie Blvd #350Wilmette
Show all (1)

Monopar Therapeutics Financials and Metrics

Monopar Therapeutics Revenue

USD

Net income (Q3, 2019)

(736.1k)

EBIT (Q3, 2019)

(759.4k)

Market capitalization (21-Feb-2020)

105.3m

Closing stock price (21-Feb-2020)

10.0

Cash (30-Sept-2019)

4.5m
Monopar Therapeutics's current market capitalization is $105.3 m.
Annual
USDFY, 2017FY, 2018

General and administrative expense

15.7m1.6m

R&D expense

935.3k1.8m

Operating expense total

16.6m3.4m

EBIT

(16.6m)(3.3m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

General and administrative expense

440.1k347.4k363.8k571.7k602.8k539.6k

R&D expense

457.1k492.6k303.7k835.6k329.3k219.8k

Operating expense total

897.3k840.0k667.5k1.4m932.1k759.4k
Annual
USDFY, 2017FY, 2018

Cash

9.0m6.9m

Current Assets

9.1m7.3m

Total Assets

9.9m7.3m

Current Liabilities

311.9k399.6k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

8.2m7.4m7.6m5.9m5.1m4.5m

Prepaid Expenses

84.9k

Current Assets

8.3m7.6m7.9m6.4m5.6m5.1m

Total Assets

9.1m8.4m7.9m6.4m5.6m5.1m
Annual
USDFY, 2017FY, 2018

Net Income

(16.6m)(3.2m)

Cash From Operating Activities

(2.6m)(2.9m)

Cash From Financing Activities

9.5m

Net Change in Cash

6.9m(2.9m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(876.3k)(820.9k)(2.3m)(1.4m)(905.7k)(3.0m)

Accounts Payable

(60.7k)

Cash From Operating Activities

(808.8k)(2.2m)(996.0k)(2.3m)

Cash From Financing Activities

(13.9k)(39.5k)
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Monopar Therapeutics Operating Metrics

FY, 2017FY, 2018Sep, 2019

Phase I Trials Products

1

Phase II Trials Products

2 2 1

Phase III Trials Products

1

Preclinical Phase Products

1 1
Show all operating metrics

Monopar Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Monopar Therapeutics Pty Ltd
Monopar Therapeutics, SARL

Monopar Therapeutics Online and Social Media Presence

Embed Graph

Monopar Therapeutics News and Updates

Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering

CHICAGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on December 19, 2019 under the symbol…

Monopar Therapeutics Frequently Asked Questions

  • When was Monopar Therapeutics founded?

    Monopar Therapeutics was founded in 2014.

  • Who are Monopar Therapeutics key executives?

    Monopar Therapeutics's key executives are Chandler D. Robinson, Christopher M. Starr and Kim R. Tsuchimoto.

  • How many employees does Monopar Therapeutics have?

    Monopar Therapeutics has 4 employees.

  • Who are Monopar Therapeutics competitors?

    Competitors of Monopar Therapeutics include Pangaea Oncology, A2 Biotherapeutics and Innate Pharma.

  • Where is Monopar Therapeutics headquarters?

    Monopar Therapeutics headquarters is located at 1000 Skokie Blvd #350Wilmette, Wilmette.

  • Where are Monopar Therapeutics offices?

    Monopar Therapeutics has an office in Wilmette.

  • How many offices does Monopar Therapeutics have?

    Monopar Therapeutics has 1 office.